LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

Search

Quanterix Corp

Închisă

SectorSănătate

6.75 -3.43

Rezumat

Modificarea prețului

24h

Curent

Minim

6.75

Maxim

7.17

Indicatori cheie

By Trading Economics

Venit

-3.5M

-34M

Vânzări

16M

40M

Marjă de profit

-83.479

Angajați

471

EBITDA

5.7M

-31M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

-14.29% downside

Statistici piață

By TradingEconomics

Capitalizare de piață

108M

346M

Deschiderea anterioară

10.18

Închiderea anterioară

6.75

Sentimentul știrilor

By Acuity

50%

50%

167 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

Quanterix Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

18 dec. 2025, 23:54 UTC

Acțiuni populare

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 dec. 2025, 23:51 UTC

Câștiguri

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 dec. 2025, 23:39 UTC

Principalele dinamici ale pieței

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 dec. 2025, 22:57 UTC

Achiziții, Fuziuni, Preluări

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 dec. 2025, 21:40 UTC

Câștiguri

Nike Sales Tick Up, But China Weakness Persists

18 dec. 2025, 23:45 UTC

Market Talk

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 dec. 2025, 23:37 UTC

Market Talk
Câștiguri

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 dec. 2025, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 dec. 2025, 23:03 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 dec. 2025, 23:02 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 dec. 2025, 23:00 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 dec. 2025, 22:59 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 dec. 2025, 22:58 UTC

Achiziții, Fuziuni, Preluări

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 dec. 2025, 22:57 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 dec. 2025, 22:56 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 dec. 2025, 22:55 UTC

Câștiguri

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dec. 2025, 21:59 UTC

Câștiguri

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dec. 2025, 21:50 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

18 dec. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 dec. 2025, 21:35 UTC

Câștiguri

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 dec. 2025, 21:31 UTC

Câștiguri

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Greater China Rev Down 17% >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q EPS 53c >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Apparel Rev $3.91B >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Equipment Rev $550M >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q N Amer Rev $5.63B >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Footwear Rev $7.66B >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Greater China Rev $1.42B >NKE

Comparație

Modificare preț

Quanterix Corp Așteptări

Obiectiv de preț

By TipRanks

-14.29% jos

Prognoză pe 12 luni

Medie 6 USD  -14.29%

Maxim 7 USD

Minim 5 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruQuanterix Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

2 ratings

0

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

5.34 / 6.015Suport & Rezistență

Termen scurt

Neutral Evidence

Termen mediu

Bullish Evidence

Termen lung

No Evidence

Sentiment

By Acuity

167 / 374 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Quanterix Corp

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
help-icon Live chat